GENPREX (GNPX) vs Virax Biolabs Group Limited (VRAX)

GENPREX and Virax Biolabs Group Limited are both Biotechnology companies. Virax Biolabs Group Limited is the larger, with a market value of $2.2M against $1.9M — 1.2× the size. Virax Biolabs Group Limited has negative trailing earnings, so its P/E is not meaningful; GENPREX trades at 0.0×. Across the 9 metrics below, Virax Biolabs Group Limited leads on 5 and GENPREX on 4.

Valuation

Metric GNPX VRAX Biotechnology median
P/E 0.03 n/m 8.50
P/S n/m n/m 9.71
P/B 0.07 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.89 0.86 0.64
EV/Sales n/m n/m 9.21
Earnings yield 3,170.61% (367.59%) (33.15%)
Free cash flow yield (1,481.72%) 0.00% (25.50%)

Profitability

Metric GNPX VRAX Biotechnology median
Gross margin 0.00% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (203.86%) 0.00% (56.36%)
Return on assets (157.40%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GNPX VRAX Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 93.48% 68.79% 30.26%
Revenue growth, 5-year CAGR — (36.88%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNPX VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 6.76 9.97 4.72
Net debt to EBITDA 0.50 1.08 0.96

Dividend

Metric GNPX VRAX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GNPX VRAX Biotechnology median
Market cap 1.88m 2.18m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack